CD24 and neoplasm: To further investigate the Tregs' role in antitumor activity of CD24+MDSC-DCs, 4T1 tumor-bearing mice were given three doses of CD24+MDSC-DCs or control MDSC-DCs cultured with ATRA as tumor vaccines from 7 days after tumor inoculation with 5-day intervals.